NASDAQ: ENGN
Engene Therapeutics Inc Stock Ownership - Who owns Engene Therapeutics?

Insider buying vs selling

Have Engene Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when ENGN insiders and whales buy or sell their stock.

ENGN Shareholders

What type of owners hold Engene Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fcpm III Services Bv14.38%9,632,561$69.35MInstitution
Forbion Growth Opportunities Fund I Cooperatief Ua10.15%6,798,362$48.95MInsider
Perceptive Advisors LLC8.76%5,869,076$42.26MInstitution
Vr Adviser LLC7.12%4,771,414$34.35MInstitution
Deep Track Capital LP6.53%4,377,572$31.52MInstitution
Cormorant Asset Management LP5.97%4,000,000$28.80MInstitution
Lumira Capital Investment Management Inc5.75%3,849,299$27.71MInsider
Blue Owl Capital Holdings LP5.02%3,360,937$24.20MInstitution
Siren LLC4.98%3,336,264$24.02MInstitution
Braidwell LP4.67%3,131,319$22.55MInstitution

1 of 3

ENGN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ENGN75.55%24.45%
FDMT80.75%19.25%Net BuyingNet Selling
CTNM79.21%7.19%Net SellingNet Selling
DNA11.77%88.23%Net SellingNet Selling
LYEL0.49%99.51%Net BuyingNet Buying

Engene Therapeutics Stock Ownership FAQ

Who owns Engene Therapeutics?

Engene Therapeutics (NASDAQ: ENGN) is owned by 87.63% institutional shareholders, 28.36% Engene Therapeutics insiders, and 0.00% retail investors. Forbion Growth Opportunities Fund I Cooperatief Ua is the largest individual Engene Therapeutics shareholder, owning 6.80M shares representing 10.15% of the company. Forbion Growth Opportunities Fund I Cooperatief Ua's Engene Therapeutics shares are currently valued at $48.95M.

If you're new to stock investing, here's how to buy Engene Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.